Rhode Island's enacted budget for fiscal year 2027 limits Medicaid coverage of GLP-1 medicines to people with type 2 diabetes. Coverage of a GLP-1 prescribed for obesity or weight management ends on October 1, 2026, and the medicines named are Wegovy, Zepbound and Saxenda. If you are on Medicaid in Rhode Island and take one of those for weight, this is the change that affects you.
Governor Dan McKee proposed the change in January 2026 as part of the FY2027 budget, citing the cost of covering these drugs, and the General Assembly adopted it in June. That makes it settled law rather than a proposal still working its way through a committee. The effective date, October 1, 2026, is what matters now, because it is the day the pharmacy counter starts answering differently.
Anyone taking a GLP-1 for type 2 diabetes is not affected. Coverage for diabetes use stays in place, so an Ozempic or Mounjaro prescription written for blood sugar is outside the change. The line the state has drawn is about the reason the drug was prescribed, not the drug itself, which means two people can be on the same medicine and land on opposite sides of this.
Without insurance, these medicines run roughly $900 to $1,500 a month. That is the number that decides what happens next for most people, and it is why the useful move is to talk with your prescriber before October 1 rather than after. There are things worth asking about: whether a diabetes diagnosis applies to you, whether the manufacturer's own savings or patient assistance programs can carry part of the cost, and what a planned taper looks like if stopping turns out to be the realistic answer.
Rhode Island is not doing this alone. The same retreat from weight-loss coverage has already played out in California, Pennsylvania, New Hampshire, South Carolina and Massachusetts over the past two years. The American Diabetes Association has publicly raised concern about the Rhode Island decision. For anyone tracking state Medicaid policy on these drugs, the pattern is the story: the coverage that expanded quickly is now being narrowed back to diabetes, state by state.
If you are in Rhode Island, on Medicaid, and taking a GLP-1 for weight, the date to work back from is October 1. Book the conversation with your prescriber now, while there is still time to look at alternatives, assistance programs and a plan you choose rather than one the calendar chooses for you.
Key details
Rhode Island's budget for fiscal year 2027 limits Medicaid coverage of GLP-1 medicines to people with type 2 diabetes.
Coverage of a GLP-1 prescribed for obesity or weight management ends on October 1, 2026. The medicines named are Wegovy, Zepbound and Saxenda.
Anyone taking a GLP-1 for type 2 diabetes is not affected by the change.
Governor McKee proposed it in January 2026 and the General Assembly adopted it in June as part of the budget.
Without insurance these medicines cost roughly $900 to $1,500 a month, so anyone in Rhode Island using one for weight management may want to talk with their prescriber before October 1.
Sources
American Diabetes Association: American Diabetes Association expresses concern over Rhode Island's decision
Originally published on GLP-1 Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.